Prenetics Global

PRE

Market cap $349M

Prenetics Global Limited (PRE) Q4 2025 Earnings Call Transcript

Small-cap stocks are crushing the market amid a major rotation away from mega tech as market breadth strengthens, boosted by declining interest rates, solid earnings, and a resilient economy. Every member of the Magnificent 7 has underperformed in 2026, with investors increasingly worried about AI capex spending and stretched valuations. Roughly 65% of Russell 2000 companies have topped Q4 earnings expectations, the best beat rate since 2021.

Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced on February 18, 2026 NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the completion of the sale of its 35% equity interest in Insighta to Tencent for total cash consideration of $70 million. The transaction provides a substantial and immediate increase in Prenetics' cash resources, further strengthening the Company's financial position as it sharpens its focus on the global expansion of IM8, its flagship consumer health brand.

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced financial results for fourth quarter and full year ended December 31, 2025.

Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Aligning with IM8 Growth Strategy NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the appointment of Dr. Darshan Shah as an independent director to its Board of Directors (the “Board”), effective February 16, 2026. Dr. Shah will also serve as a member of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced Pre-Market on February 18, 2026 NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the completion of the sale of its 35% equity interest in Insighta to Tencent for total cash consideration of $70 million. The transaction provides a substantial and immediate increase in Prenetics' cash resources, further strengthening the Company's financial position as it sharpens its focus on the global expansion of IM8, its flagship consumer health brand.

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced Formula 1 phenom Ollie Bearman as its newest Global Ambassador and a shareholder. This partnership marks another milestone for IM8 as it continues to capture interest and align with world-class athletes who embody peak performance and a commitment to health excellence.

Prenetics: Strong Liquidity And Rapidly Rising Revenue

Prenetics Global Limited is rated a buy, with a projected 150% upside based on forward EV/S and robust revenue growth from IM8. PRE has been working to reduce its direct costs, with a sequential improvement of 9% (QoQ) while increasing IM8's gross margin by 8 percentage points on a sequential basis. My calculation shows that Prenetics Global has a cash runway of about 18 months with a net burn rate of about $25 million in nine months.

Prenetics Global (PRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).